You are here

• Home
• About AstraZeneca US
• Newsroom

• News

The following shows headlines of news articles, starting from most recent.

• Pages
• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• Next

• • Jun 26, 2010
  • ONGLYZA™ (saxagliptin) with metformin as initial combination therapy provided 76-week long-term glycemic control in treatment-naïve adults with type 2 diabetes  
• • Jun 23, 2010
  • AstraZeneca and Targacept initiate Phase 3 clinical development of TC-5214 as an adjunct treatment for major depressive disorder  
• • Jun 22, 2010
  • Dapagliflozin as monotherapy demonstrated improved glycemic control in treatment-naïve adults with type 2 diabetes  
• • Jun 7, 2010
  • First phase III trial with definitive results in advanced medullary thyroid cancer shows statistically significant extension of progression free survival for patients  
• • Jun 2, 2010
  • FDA updates U.S. product labels for LABA-containing medications including AstraZeneca’s SYMBICORT  
• • Jun 1, 2010
  • AstraZeneca recognized for eco-leadership  
• • May 25, 2010
  • The Opportunity Center and AstraZeneca partner to educate local students with disabilities  
• • May 21, 2010
  • AstraZeneca donates $1 million for Christiana Care Health System’s Wilmington Hospital project  
• • May 19, 2010
  • AstraZeneca and Carolina Family Health Centers, Inc. provide medicines to North Carolina’s uninsured  
• • May 14, 2010
  • Phase II data contributes to understanding of cediranib in recurrent glioblastoma  

• Pages
• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed